Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by on Aug 26th, 2026

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.00.

AUTL has been the topic of a number of research analyst reports. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th.

Read Our Latest Research Report on AUTL

Institutional Trading of Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after acquiring an additional 11,381 shares during the period. Jane Street Group LLC lifted its stake in shares of Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after buying an additional 91,222 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock worth $375,000 after buying an additional 78,058 shares during the period. The Manufacturers Life Insurance Company grew its stake in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after acquiring an additional 942,540 shares during the period. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $2.44 on Wednesday. The stock has a 50-day simple moving average of $1.76 and a 200 day simple moving average of $1.62. The stock has a market capitalization of $649.43 million, a price-to-earnings ratio of -2.30 and a beta of 2.07. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. Autolus Therapeutics has a 12-month low of $1.17 and a 12-month high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, research analysts anticipate that Autolus Therapeutics will post -0.75 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Featured Articles

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.